Literature DB >> 12772

Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs.

C J Niemegeers, K H Schellekens, W F Van Bever, P A Janssen.   

Abstract

Sufentanil (R 30 730), N-[4-methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, is a chemically novel, highly potent and extremely safe intravenous morphine-like agent in laboratory animals. In mice R 30 730 i.v. is 2304 times more potent than morphine (hot plate ED50's: 0.0028 and 6.45 mg/kg, respectively). The i.v. safety margin of R 30 730 in mice is 1 : 6 679 (LD50 = 18.7 mg/kg). Under the same experimental conditions the safety margin of pethidine is 1 : 7.97, of morphine 1 : 34.9 and of fentanyl 1 : 454. In rats R 30 730 i.v. is 4521 times more potent than morphine (tail withdrawal test ED50's: 0.00071 and 3.21 mg/kg, respectively). The i.v. safety margin of R 30 730 in rats is 1 : 25 211 (LD50 : 17.9 mg/kg). Under the latter experimental conditions the safety margin of pethidine is 1 : 4.80, of morphine 1 : 69.5 and of fentanyl 1 : 277. In dogs R 30 730 i.v. is 2429 times more potent than morphine (apomorphine antagonism test ED50's: 0.00028 and 0.68 mg/kg, respectively). The i.v. safety margin in dogs is approximately 1 : 50 000, the LD50 being +/- 14.0 mg/kg. All morphine-like effects of R 30 730 are immediately antagonized by nalorphine. These pharmacological findings are relevant in connection to the increasing interest for use of morphinomimetics in anesthesia.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 12772

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  17 in total

1.  Withdrawal following sufentanil/propofol and sufentanil/midazolam. Sedation in surgical ICU patients: correlation with central nervous parameters and endogenous opioids.

Authors:  Maria Korak-Leiter; Rudolf Likar; Michael Oher; Ernst Trampitsch; Gerda Ziervogel; Joseph V Levy; Enno C Freye
Journal:  Intensive Care Med       Date:  2005-02-16       Impact factor: 17.440

Review 2.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 3.  Sufentanil. A review of its pharmacological properties and therapeutic use.

Authors:  J P Monk; R Beresford; A Ward
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 4.  Pharmacotherapy of opioids: present and future developments.

Authors:  T F Meert
Journal:  Pharm World Sci       Date:  1996-01

Review 5.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

6.  Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.

Authors:  John L Neumeyer; Bin Zhang; Tangzhi Zhang; Anna W Sromek; Brian I Knapp; Dana J Cohen; Jean M Bidlack
Journal:  J Med Chem       Date:  2012-04-04       Impact factor: 7.446

7.  Proceedings of the British Pharmacological Society. 10th-12th September, 1980. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

8.  A sensitive radioimmunoassay for fentanyl. Plasma level in dogs and man.

Authors:  M Michiels; R Hendriks; J Heykants
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of the newer intravenous anaesthetic agents.

Authors:  P J Davis; D R Cook
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

10.  Epidural sufentanil for post-caesarean section analgesia: lack of benefit of epinephrine.

Authors:  G H McMorland; M J Douglas; J H Kim; A A Kamani; J E Swenerton; J Berkowitz; P L Ross; L Palmer; D M Ansley
Journal:  Can J Anaesth       Date:  1990-05       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.